Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, Gonzalez RM, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova OV, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue BJ, Grajales-Cruz AF, Castaneda Puglianini OA, Liu HD, Nishihori T, Freeman CL, Brayer JB, Shain KH, Baz RC, Locke FL, Alsina M, Sidana S, Hansen DK.
Logue JM, et al. Among authors: patil s.
Blood Adv. 2022 Dec 27;6(24):6109-6119. doi: 10.1182/bloodadvances.2022008320.
Blood Adv. 2022.
PMID: 35939783
Free PMC article.